pharmaphorum

Intellia trumpets CRISPR drug data, but shares fall

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its shares ...
The Lancet

Prognostic accuracy of clinical markers of postpartum bleeding in predicting maternal mortality or severe morbidity: a WHO individual participant data meta-analysis

aoUNDP-UNFPA-UNICEF-WHO-World Bank Special Program of Research, Development, and Research Training in Human Reproduction, Department of Sexual and Reproductive Health and Research, WHO, Geneva, ...